The objective of a phase II cancer clinical trial is to screen a treatment that can produce a similar or better response rate compared to the current treatment results. This screening is usually carried out in two stages as proposed by Simon. For ineffective treatment, the trial should terminate at
Optimal flexible designs in phase II clinical trials
β Scribed by T. Timothy Chen; Tie-Hua Ng
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 107 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0277-6715
No coin nor oath required. For personal study only.
β¦ Synopsis
In the conduct of a phase II cancer clinical trial, patients usually enter in two stages. If the response rate from the first stage is low, then the study terminates. Within various two-stage designs, Simon proposed the optimal and minimax criteria. In the co-operative group setting, practical considerations make it difficult to arrive at the planned sample size exactly. Green and Dahlberg proposed and compared several flexible designs. In this paper, we explicitly define a flexible design as a collection of two-stage designs where the first stage size is in a set of consecutive values (n , 2 , n I ) and the second stage size is also in another set of consecutive values (N , 2 , N I ), and each of k possible designs has the same probability of occurrence. We apply Simon's optimal and minimax criteria to flexible designs for phase II trials in order to minimize the number of patients tested on an ineffective drug. 1998 John Wiley & Sons, Ltd. This paper was produced under the auspices of the US Government and is therefore not subject to copyright in the US.
π SIMILAR VOLUMES
Simon's optimal two-stage design is widely used to conduct single-dose phase II clinical trials. We extend this basic methodology to the situation where the researcher desires to test an experimental drug for activity at a low dose level, but is willing to increase the dose part-way through the tria